-
Management Board: Highlights of June 2019 meeting
Management Board: Highlights of June 2019 meeting
-
Management Board: Highlights of June 2019 meeting
Management Board: Highlights of June 2019 meeting
At its June meeting, EMA’s Management Board heard an update on the Agency’s preparations for Brexit, a positive assessment of EMA’s operations in 2018 and an update on the development of the Clinical Trials Information System (CTIS).
-
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 June 2019
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 June 2019
-
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 June 2019
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 June 2019
The PRAC starts a new review of leuprorelin medicines after reports of handling errors during preparation and administration.
-
Strengthening engagement between EMA and general practitioners / family physicians
Strengthening engagement between EMA and general practitioners / family physicians
-
Strengthening engagement between EMA and general practitioners / family physicians
Strengthening engagement between EMA and general practitioners / family physicians
EMA, the European Union of General Practitioners (UEMO), the European section of the World Organization of Family doctors (WONCA) and the European Forum for Primary Care (EFPC) sign a joint statement committing to strengthened collaboration.
-
Engaging early with medicine developers to combat antimicrobial resistance
Engaging early with medicine developers to combat antimicrobial resistance
-
Engaging early with medicine developers to combat antimicrobial resistance
Engaging early with medicine developers to combat antimicrobial resistance
EMA is opening its forum for early dialogue on innovative medicines to the developers of new antimicrobials.
